drugset / Trial / NCT00307294
Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to evaluate PSA response rates of the combination of Doxil and Thalidomide in patients with AIPC who have failed chemotherapy. Secondary objectives include: 1) To evaluate the clinical response rate of this combination on measurable disease 2) To evaluate overall survival for this combination.
Timeline
- Start
- 2006-03
- Primary completion
- 2012-01
- Completion
- 2012-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | 40 mg/m2 | Intravenous |
| Subject | Thalidomide | Other / unclassified | 200 mg | Oral |